Zydus Lifesciences has partnered with Bioeq for the U.S. commercialization rights of NUFYMCO®, an interchangeable biosimilar to Lucentis®. The NUFYMCO® Biologics License Application (BLA) has been approved by the USFDA. Bioeq will handle development, manufacturing, and supply, while Zydus will lead commercialization. The partnership expands Zydus’ biosimilar business in the U.S. The total addressable market is approximately US$210 million.
Strategic Biosimilar Partnership
Zydus Lifesciences Global FZE, a subsidiary of Zydus Lifesciences, has entered into a strategic partnership with Bioeq for NUFYMCO®. This agreement grants Zydus the rights for licensing, supply, and commercialization in the U.S. market. The announcement was made on December 23, 2025.
Responsibilities and Approvals
Bioeq will oversee the development, manufacturing, and registration of NUFYMCO®. Zydus will be responsible for its commercialization within the U.S. The Biologics License Application (BLA) for NUFYMCO® has already been approved by the USFDA as of December 18, 2025.
Market Opportunity and Outlook
The partnership allows Zydus to leverage Bioeq’s expertise and expand its biosimilar offerings in the U.S. The collaboration aims to provide broader access to affordable ophthalmology care. The total addressable market opportunity for biosimilar Ranibizumab in the US is approximately US$210 million as per IQVIA MAT Sep 2025.
Source: BSE